Sorafenib for preserving insulin in new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether the drug sorafenib can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may slow the progression of the disease and reduce the need for insulin injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have been diagnosed with type 1 diabetes within the last year.
- You must test positive for at least one diabetes-related antibody (such as GAD, IA-2, or ZnT8).
- Your pancreas must still be making some insulin, as shown by a C-peptide level greater than 200 pmol/L.
- If you are of childbearing age, you must agree to use effective birth control during the study.
- You must not have serious health conditions like active infections, heart disease, or significant kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
This study tests if denosumab, a drug normally used for bone health, can help preserve your body's own insulin production in type 1 diabetes. It might slow the loss of insulin-making cells, helping you maintain better blood sugar control over time.
This study tests new treatments for people with long-standing type 1 diabetes who also have early signs of heart or kidney disease. The goal is to see if these treatments can help protect the heart and kidneys.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.